JP6898240B2 - Ｔ細胞前駆細胞を生成するための方法 - Google Patents

Ｔ細胞前駆細胞を生成するための方法 Download PDF

Info

Publication number
JP6898240B2
JP6898240B2 JP2017537016A JP2017537016A JP6898240B2 JP 6898240 B2 JP6898240 B2 JP 6898240B2 JP 2017537016 A JP2017537016 A JP 2017537016A JP 2017537016 A JP2017537016 A JP 2017537016A JP 6898240 B2 JP6898240 B2 JP 6898240B2
Authority
JP
Japan
Prior art keywords
cells
medium
progenitor cells
cell
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017537016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531448A (ja
JP2017531448A5 (enExample
Inventor
マリーナ カヴァッツァーナ
マリーナ カヴァッツァーナ
イザベル アンドレ−シュムッツ
イザベル アンドレ−シュムッツ
シャンタル ラグレル−ペイルー
シャンタル ラグレル−ペイルー
サリマ ハサイン−ベイ−アビナ
サリマ ハサイン−ベイ−アビナ
クリスティアン ライマン
クリスティアン ライマン
シャプドレーヌ コリーヌ ド
シャプドレーヌ コリーヌ ド
エマニエル シックス
エマニエル シックス
Original Assignee
アシスタンス パブリック−ホピトー デ パリ
アシスタンス パブリック−ホピトー デ パリ
フォンダシオン イマジネ アンスティチュ デ マラディース ジェネティクス
フォンダシオン イマジネ アンスティチュ デ マラディース ジェネティクス
ユニベルシテ パリ デカルト
ユニベルシテ パリ デカルト
インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル （インセルム）
インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル （インセルム）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アシスタンス パブリック−ホピトー デ パリ, アシスタンス パブリック−ホピトー デ パリ, フォンダシオン イマジネ アンスティチュ デ マラディース ジェネティクス, フォンダシオン イマジネ アンスティチュ デ マラディース ジェネティクス, ユニベルシテ パリ デカルト, ユニベルシテ パリ デカルト, インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル （インセルム）, インスティチュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル （インセルム） filed Critical アシスタンス パブリック−ホピトー デ パリ
Publication of JP2017531448A publication Critical patent/JP2017531448A/ja
Publication of JP2017531448A5 publication Critical patent/JP2017531448A5/ja
Application granted granted Critical
Publication of JP6898240B2 publication Critical patent/JP6898240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
JP2017537016A 2014-10-06 2015-10-05 Ｔ細胞前駆細胞を生成するための方法 Active JP6898240B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1459539A FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t
FR1459539 2014-10-06
PCT/EP2015/072889 WO2016055396A1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020209370A Division JP2021072779A (ja) 2014-10-06 2020-12-17 Ｔ細胞前駆細胞を生成するための方法

Publications (3)

Publication Number Publication Date
JP2017531448A JP2017531448A (ja) 2017-10-26
JP2017531448A5 JP2017531448A5 (enExample) 2018-11-15
JP6898240B2 true JP6898240B2 (ja) 2021-07-07

Family

ID=52102849

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017537016A Active JP6898240B2 (ja) 2014-10-06 2015-10-05 Ｔ細胞前駆細胞を生成するための方法
JP2020209370A Pending JP2021072779A (ja) 2014-10-06 2020-12-17 Ｔ細胞前駆細胞を生成するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020209370A Pending JP2021072779A (ja) 2014-10-06 2020-12-17 Ｔ細胞前駆細胞を生成するための方法

Country Status (11)

Country Link
US (1) US12071635B2 (enExample)
EP (2) EP3204492B1 (enExample)
JP (2) JP6898240B2 (enExample)
CA (1) CA2963756C (enExample)
DK (1) DK3204492T3 (enExample)
ES (1) ES2914082T3 (enExample)
FR (1) FR3026744B1 (enExample)
HU (1) HUE059468T2 (enExample)
PL (1) PL3204492T3 (enExample)
PT (1) PT3204492T (enExample)
WO (1) WO2016055396A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076342B2 (en) 2016-04-08 2024-09-03 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
CA3096812A1 (en) * 2018-04-10 2019-10-17 Stichting Sanquin Bloedvoorziening Chimeric notch receptors
CN116615461A (zh) 2020-11-30 2023-08-18 醣基生医股份有限公司 用于富集细胞的抗体
US20260152721A1 (en) 2021-11-04 2026-06-04 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
KR20250152088A (ko) 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
WO2025012449A1 (en) * 2023-07-12 2025-01-16 Smart Immune Biobank of cellular banks having specific homozygous hla haplotypes and uses thereof for treating patients
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
WO2025255678A1 (en) * 2024-06-14 2025-12-18 Stemcell Technologies Canada Inc. Compositions and methods for generating lymphoid lineage cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999028486A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
EP1666589B1 (en) * 2003-08-22 2010-02-17 Takara Bio Inc. Process for producing cytotoxic lymphocytes
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CA2737193A1 (en) 2008-09-12 2010-03-18 Universidade Federal De Sao Paulo - Unifesp Ischemic tissue cell therapy
US8772028B2 (en) 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
US8871510B2 (en) * 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
EP3590520B1 (en) 2010-04-09 2021-12-29 Fred Hutchinson Cancer Research Center Compositions for providing hematopoietic function without hla matching
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20150352180A1 (en) * 2013-01-11 2015-12-10 The Trustee Of The University Of Pennsylvania Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
JP6661544B2 (ja) 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したｔ細胞の自動生成法
WO2016039933A1 (en) * 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders

Also Published As

Publication number Publication date
EP3204492A1 (fr) 2017-08-16
PL3204492T3 (pl) 2022-07-25
JP2017531448A (ja) 2017-10-26
CA2963756A1 (fr) 2016-04-14
ES2914082T3 (es) 2022-06-07
EP3204492B1 (fr) 2022-03-09
ES2914082T8 (es) 2022-06-16
WO2016055396A1 (fr) 2016-04-14
US12071635B2 (en) 2024-08-27
EP4036224A1 (fr) 2022-08-03
HUE059468T2 (hu) 2022-12-28
US20180208895A1 (en) 2018-07-26
PT3204492T (pt) 2022-05-30
CA2963756C (fr) 2024-01-02
FR3026744B1 (fr) 2024-04-19
JP2021072779A (ja) 2021-05-13
DK3204492T3 (da) 2022-06-07
FR3026744A1 (fr) 2016-04-08

Similar Documents

Publication Publication Date Title
JP2021072779A (ja) Ｔ細胞前駆細胞を生成するための方法
US11642376B2 (en) Method for generating T cell progenitors
KR20180057641A (ko) 자연살해 세포의 증식방법
KR20110006705A (ko) 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
US20130142766A1 (en) Production method for cell populations
CA2536492A1 (en) Process for producing cytotoxic lymphocytes
EP4600352A1 (en) T cell production method
JP5485139B2 (ja) 遺伝子導入細胞の製造方法
HK40081656A (en) Method for generating t cells progenitors
WO2022210399A1 (ja) 遺伝子改変細胞およびその製造方法
WO2025094915A1 (ja) 細胞傷害性ｔ細胞の製造方法
HK40017982A (en) Method for generating t cells progenitors
HK40017982B (en) Method for generating t cells progenitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201217

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210402

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210610

R150 Certificate of patent or registration of utility model

Ref document number: 6898240

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250